Cargando…
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
The molecular underpinnings of HER2-low and HER2-0 (IHC 0) breast tumors remain poorly defined. Using genomic findings from 1039 patients with HER2-negative metastatic breast cancer undergoing next-generation sequencing from 7/2013-12/2020, we compare results between HER2-low (n = 487, 47%) and HER2...
Autores principales: | Tarantino, P., Gupta, H., Hughes, M. E., Files, J., Strauss, S., Kirkner, G., Feeney, A.-M., Li, Y., Garrido-Castro, A. C., Barroso-Sousa, R., Bychkovsky, B. L., DiLascio, S., Sholl, L., MacConaill, L., Lindeman, N., Johnson, B. E., Meyerson, M., Jeselsohn, R., Qiu, X., Li, R., Long, H., Winer, E. P., Dillon, D., Curigliano, G., Cherniack, A. D., Tolaney, S. M., Lin, N. U. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657399/ https://www.ncbi.nlm.nih.gov/pubmed/37980405 http://dx.doi.org/10.1038/s41467-023-43324-w |
Ejemplares similares
-
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
por: Schlam, Ilana, et al.
Publicado: (2022) -
How I treat HER2-low advanced breast cancer
por: Schlam, Ilana, et al.
Publicado: (2023) -
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023) -
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
por: Grinshpun, Albert, et al.
Publicado: (2023) -
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
por: Antonarelli, G., et al.
Publicado: (2023)